首頁 > 市場調查報告書 > 製藥

感染疾病

市場調查報告書

商品編碼

1490033

急性細菌性皮膚和皮膚結構感染疾病的全球市場：按藥物類型、感染類型、給藥途徑、分銷管道和地區

Acute Bacterial Skin And Skin Structure Infections Market, By Drug Type, By Infection Type, By Route of Administration, By Distribution Channel, By Geography

出版日期: 2024年05月09日 | 出版商:

Coherent Market Insights | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

2024年全球急性細菌性皮膚和皮膚結構感染疾病市場規模估計達38.425億美元，2024年至2031年年複合成長率為5.8%，2031年將達到57.017億美元。

報告範圍		報告詳情
基準年	2023年	2024年市場規模	38.425 億美元
實際資料	2019-2023	預測期	2024-2031
預測2024-2031年年複合成長率：	5.8%	2031年金額預測	57.017 億美元

圖：急性細菌性皮膚和皮膚結構感染疾病的區域比例（%）（2024年）

急性細菌性皮膚和皮膚結構感染疾病（ABSSSI）是指影響皮膚及周圍組織和結構的常見細菌感染疾病，包括主要皮膚膿腫、蜂窩性組織炎以及感染的傷口和潰瘍。引起 ABSSSI 的常見細菌包括金黃色葡萄球菌和化膿性鏈球菌。由於抗生素抗藥性的增加以及肥胖、糖尿病和生活方式改變等危險因子的增加，ABSSSI 的全球發生率日益增加。

市場動態：

由於世界老年人口的增加和糖尿病等合併症的增加，ABSSSI 的風險日益增加。根據國際糖尿病聯盟的資料，2019年約有4.63億20歲至79歲的成年人患有糖尿病，預計到2045年這一數字將增加至7億以上。老年人也更容易受到皮膚和軟組織感染疾病。快速的都市化和生活方式的改變損害了免疫健康，進一步增加了全球 ABSSSI 的疾病負擔。然而，有關臨床試驗和藥物核准的嚴格規定可能會阻礙市場成長。新型抗菌劑的持續研究和開發以及先進創傷護理療法的快速普及為市場帶來了有利的機會。

本研究的主要特點

本報告詳細分析了全球急性細菌性皮膚和皮膚結構感染疾病市場，包括市場規模（百萬美元）和年複合成長率（CAGR%）。
強調了各個細分市場的潛在收益成長機會，並說明了該市場有吸引力的投資提案矩陣。
提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景、主要企業採取的競爭策略等的主要考察。
根據公司亮點、產品系列、主要亮點，實績和策略等參數，對全球急性細菌性皮膚和皮膚結構感染疾病市場的主要企業進行了分析。
主要企業包括 Fresenius SE & Co.KGaA、Pfizer, Inc.、Amneal Pharmaceuticals LLC、Intas Pharmaceuticals Ltd.、Cadila Healthcare Ltd.、Glenmark Pharmaceuticals Ltd.、GSK plc、Sun Pharmaceutical Industries Ltd.、Aurobindo Pharma Ltd.、AbbVie、GSK plc、Sun Pharmaceutical Industries Ltd.、Aurobindo Pharma Ltd.、AbbVie, Inc.、Melinta Therapeutics, Inc.、Accord Healthcare Ltd.、Merck &Co, Inc.、Teva Pharmaceutical Industries Ltd.、Partek Pharmaceuticals, Inc. 等。
本報告的見解使負責人和公司經營團隊能夠就未來的產品發布、類型升級、市場擴張和行銷策略做出明智的決策。
全球急性細菌性皮膚和皮膚結構感染疾病市場迎合了該行業的各種相關人員，如投資者、供應商、產品製造商、經銷商、新進業者和金融分析師。
相關人員可以透過用於分析全球急性細菌性皮膚和皮膚結構感染疾病市場的各種策略矩陣來促進決策。

公司簡介
- Fresenius SE &Co. KGaA
- Pfizer, Inc.
- Amneal Pharmaceuticals LLC
- Intas Pharmaceuticals Ltd.
- Cadila Healthcare Ltd.
- Glenmark Pharmaceuticals Ltd
- GSK plc
- Sun Pharmaceutical Industries Ltd.
- Aurobindo Pharma Ltd.
- AbbVie, Inc.
- Melinta Therapeutics, Inc.
- Accord Healthcare Ltd.
- Merck &Co., Inc.
- Teva Pharmaceutical Industries Ltd.
- Paratek Pharmaceuticals, Inc.

第11章分析師建議

第12章參考文獻與調查方法

簡介目錄

Product Code: CMI1531

Global acute bacterial skin and skin structure infections market is estimated to be valued at USD 3,842.5 Mn in 2024 and is expected to reach USD 5,701.7 Mn by 2031, exhibiting a compound annual growth rate (CAGR) of 5.8% from 2024 to 2031.

Report Coverage		Report Details
Base Year:	2023	Market Size in 2024:	US$ 3,842.5 Mn
Historical Data for:	2019 to 2023	Forecast Period:	2024 to 2031
Forecast Period 2024 to 2031 CAGR:	5.80%	2031 Value Projection:	US$ 5,701.7 Mn

Figure. Acute Bacterial Skin And Skin Structure Infections Marke Share (%), By Region, 2024

Acute Bacterial Skin And Skin Structure Infections Market - IMG1

Acute bacterial skin and skin structure infections (ABSSSI) refer to common bacterial infections that involve the skin and surrounding tissue or structures such as major cutaneous abscesses, cellulitis, and infected wounds or ulcers. Some of the common bacteria that cause ABSSSI include Staphylococcus aureus and Streptococcus pyogenes. With rising antibiotic resistance and increasing risk factors such as obesity, diabetes, and lifestyle changes, the global incidence of ABSSSI increases.

Market Dynamics:

Growing geriatric population worldwide coupled with rising prevalence of comorbidities such as diabetes increases the risk of ABSSSI. According to the International Diabetes Federation, approximately 463 million adults aged 20-79 years lived with diabetes in 2019, and this figure is projected to rise to over 700 million by 2045. The elderly are also more susceptible to skin and soft tissue infections. Rapid urbanization and changes in lifestyle that compromise immune health have further increased the ABSSSI disease burden globally. However, stringent regulations pertaining to clinical trials and drug approvals can hinder the market growth. Ongoing R&D for novel antibacterial medications and rapid adoption of advanced wound care therapies offers lucrative opportunities in the market.

Key Features of the Study:

This report provides an in-depth analysis of the global acute bacterial skin and skin structure infections market, and provides market size (USD Mn) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year
It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market.
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players.
It profiles key players in the global acute bacterial skin and skin structure infections market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
Key companies covered as a part of this includes Fresenius SE & Co. KGaA, Pfizer, Inc., Amneal Pharmaceuticals LLC, Intas Pharmaceuticals Ltd., Cadila Healthcare Ltd., Glenmark Pharmaceuticals Ltd, GSK plc, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Ltd., AbbVie, Inc., Melinta Therapeutics, Inc., Accord Healthcare Ltd., Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., Paratek Pharmaceuticals, Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
Global acute bacterial skin and skin structure infections market caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global acute bacterial skin and skin structure infections market.

Detailed Segmentation-

By Drug Type:
- Oral & Parenteral Antibiotics
- Oritavancin
- Delafloxacin
- Vancomycin
- Others
- Topical Antibiotics
- Hydrogen Peroxide
- Fusidic Acid
- Mupirocin
- Retapamulin
By Infection Type:
- Hospital Acquired ABSSSI
- Community Acquired ABSSSI
By Route of Administration:
- Oral
- Parenteral
- Topical
By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
Company Profiles:
- Fresenius SE & Co. KGaA
- Pfizer, Inc.
- Amneal Pharmaceuticals LLC
- Intas Pharmaceuticals Ltd.
- Cadila Healthcare Ltd.
- Glenmark Pharmaceuticals Ltd
- GSK plc
- Sun Pharmaceutical Industries Ltd.
- Aurobindo Pharma Ltd.
- AbbVie, Inc.
- Melinta Therapeutics, Inc.
- Accord Healthcare Ltd.
- Merck & Co., Inc.
- Teva Pharmaceutical Industries Ltd.
- Paratek Pharmaceuticals, Inc.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Drug Type
- Market Snapshot, By Infection Type
- Market Snapshot, By Route of Administration
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Opportunities
Impact Analysis
Market Trends
Key Developments
Regulatory Scenario
Manufacturer Revenue
Adoption of Non-invasive Sensor Technologies
Acquisitions and Partnerships Scenario
Product Launches/Approvals
Funding and Investments
PEST Analysis
Porter's Analysis

4. Global Acute Bacterial Skin and Skin Structure Infections Market- Impact of Coronavirus (COVID-19) Pandemic

Overall Impact
Government Initiatives
COVID-19 Impact on the Market

5. Global Acute Bacterial Skin and Skin Structure Infections Market, By Drug Type, 2019 - 2031, (USD Mn)

Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2019 - 2031
- Segment Trends
Oral & Parenteral Antibiotics
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
Oritavancin
Delafloxacin
Vancomycin
Others
Topical Antibiotics
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
Hydrogen Peroxide
Fusidic Acid
Mupirocin
Retapamulin

6. Global Acute Bacterial Skin and Skin Structure Infections Market, By Infection Type, 2019 - 2031, (USD Mn)

Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2019 - 2031
- Segment Trends
Hospital Acquired ABSSSI
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
Community Acquired ABSSSI
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)

7. Global Acute Bacterial Skin and Skin Structure Infections Market, By Route of Administration, 2019 - 2031, (USD Mn)

Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2019 - 2031
- Segment Trends
Oral
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
Parenteral
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
Topical
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)

8. Global Acute Bacterial Skin and Skin Structure Infections Market, By Distribution Channel, 2019 - 2031, (USD Mn)

Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2019 - 2031
- Segment Trends
Hospital Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
Retail Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
Online Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)

9. Global Acute Bacterial Skin and Skin Structure Infections Market, By Region, 2019 - 2031, (USD Mn)

Introduction
- Market Share Analysis, By Region, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, For Region, 2019-2031
- Regional Trends
  - North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Infection Type, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Mn)
  - U.S.
  - Canada
  - Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Infection Type, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Mn)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
  - Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Infection Type, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Mn)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
  - Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Infection Type, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Mn)
  - China
  - India
  - Japan
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
  - Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Infection Type, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Mn)
  - GCC
  - Israel
  - Rest of Middle East
  - Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Infection Type, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2019 - 2031, (USD Mn)
  - North Africa
  - Central Africa
  - South Africa

10. Competitive Landscape

Company Profiles
- Fresenius SE & Co. KGaA
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Pfizer, Inc.
- Amneal Pharmaceuticals LLC
- Intas Pharmaceuticals Ltd.
- Cadila Healthcare Ltd.
- Glenmark Pharmaceuticals Ltd
- GSK plc
- Sun Pharmaceutical Industries Ltd.
- Aurobindo Pharma Ltd.
- AbbVie, Inc.
- Melinta Therapeutics, Inc.
- Accord Healthcare Ltd.
- Merck & Co., Inc.
- Teva Pharmaceutical Industries Ltd.
- Paratek Pharmaceuticals, Inc.